Cachexia (Wasting Syndrome)
Severe weight loss, muscle wasting, and loss of appetite associated with chronic illness. Cannabis and cannabinoids have moderate evidence for stimulating appetite and inducing weight gain in HIV/AIDS-associated and cancer-associated wasting.
- 30 states
- QUALIFYING IN
- Moderate
- EVIDENCE
- R64
- ICD-10
Reviewed by Laura H. Meyer
Qualifying states
What it is
Cachexia is a complex metabolic syndrome characterized by severe involuntary weight loss, muscle wasting, anorexia (loss of appetite), and weakness in the setting of chronic illness. Most commonly cancer, HIV/AIDS, end-stage organ failure, and severe chronic obstructive pulmonary disease. It is distinct from simple starvation: nutritional support alone often fails to reverse the underlying metabolic dysregulation.
Cachexia substantially worsens prognosis and quality of life across the conditions it accompanies.
Cannabis and cannabis-derived therapies
The 2017 NASEM consensus report identified moderate evidence that cannabis improves appetite and induces weight gain in HIV/AIDS-associated wasting. Dronabinol (Marinol), a synthetic THC, has been FDA-approved since 1992 for AIDS-related anorexia and is also approved for chemotherapy-induced nausea and vomiting.
Evidence in cancer cachexia is more mixed: while patient-reported appetite improvement is consistent, randomized trials show inconsistent effects on objective weight outcomes. Cachexia is a qualifying condition under most US medical cannabis programs, typically requiring documentation of severe weight loss (often >10% over six months) as part of certification.
Frequently asked questions
What is the difference between cachexia and simple weight loss?
Cachexia is a complex metabolic syndrome involving severe involuntary weight loss, muscle wasting, anorexia, and weakness in the setting of chronic illness. Unlike simple starvation, cachexia involves underlying metabolic dysregulation that nutritional support alone often cannot reverse.
Is dronabinol FDA-approved for cachexia?
Dronabinol is FDA-approved specifically for anorexia associated with weight loss in patients with AIDS. It is not specifically labeled for cancer cachexia, though it is sometimes prescribed off-label for that indication.
What does NASEM say about cannabis for weight gain?
The 2017 NASEM report identifies moderate evidence that cannabis and cannabinoids improve appetite and weight gain in HIV/AIDS-associated wasting. Evidence for cancer-associated cachexia is more limited.
Why isn't cachexia always called by that name in state programs?
State medical-cannabis statutes use various overlapping terms (cachexia, severe wasting syndrome, severe and involuntary weight loss) to describe the same clinical condition. Older statutes sometimes use only cachexia, while newer programs enumerate the broader phrasing.
Sources
- NASEM: The Health Effects of Cannabis and Cannabinoids (2017)accessed May 15, 2026
- FDA: Dronabinol (Marinol) prescribing informationaccessed May 15, 2026